Distribution of Candida albicans and Non-albicans Candida Species Causing Vaginitis in Iran: A Review

Document Type : Review Article

Authors

1 Department of Laboratory Sciences, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

10.22038/psj.2025.86529.1464

Abstract

Introduction:
Due to the rising prevalence of non-albicans Candida (NAC) species in vulvovaginal candidiasis (VVC), the present study on the geographical distribution of C. albicans and NAC species in Iran is of considerable importance. Early identification of rare species can significantly improve prevention and treatment strategies, thereby contributing to meaningful advancements in this field.
 
Materials and Methods:
This review examined studies conducted in Iran between 2009 and 2024, published in both Persian and English languages in the Google Scholar database. These studies covered reports from various cities, including Zabol, Gorgan, Sari, Damavand, Ilam, Tehran, Jahrom, Ahvaz, Birjand, Mashhad, Kerman, Babol, Qazvin, Ardabil, Babolsar, Shiraz, Yasuj, Gonabad, Kashan, Fasa, Torbat-e Jam, and Neyshabur.
 Results:
The NAC species reported in Iran included C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, C. kefyr, C. africana, C. lusitaniae, C. guilliermondii, C. orthopsilosis, C. dubliniensis, C. sake, C. intermedia, and C. famata. The highest prevalence of VVC in Iran was attributed to C. albicans, with a prevalence rate of 66.1% (2,975 out of 4,500 VVC cases), which is relatively high on a global scale. The NAC species accounted for 24.9% of cases (1,121 out of 4,500 VVC cases), with C. glabrata being the most common NAC species and exhibiting a prevalence rate of 11.7% (530 out of 4,500 VVC cases).
 Conclusion:
The distribution of NAC species across various cities and regions of Iran has revealed significant variations. The reported species not only differ between cities but also within different areas of the same locality, emphasizing the need for localized surveillance and region-specific treatment strategies.

Keywords

Main Subjects

References

  1. Andes DR, Safdar N, Baddley JW, Alexander B, Brumble L, Freifeld A, et al. The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant‐Associated Infection Surveillance Network (TRANSNET). Transplant Infectious Disease. 2016;18(6): 921-31.
  2. Whibley N, Gaffen SL. Beyond Candida albicans: Mechanisms of immunity to non-albicans Candida species. Cytokine. 2015; 76(1): 42-52.
  3. Spinillo A, Capuzzo E, Gulminetti R, Marone P, Colonna L, Piazzi G. Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. American journal of obstetrics and gynecology. 1997;176(1):138-41.
  4. Blostein F, Levin-Sparenberg E, Wagner J, Foxman B. Recurrent vulvovaginal candidiasis. Annals of Epidemiology. 2017;27(9):575-82. e3.
  5. Kord Z, Fata A, Zarrinfar H. Molecular Identification of Candida species isolated from patients with vulvovaginitis for the first time in Mashhad. The Iranian Journal of Obstetrics, Gynecology and Infertility. 2017;20(4):50-7.
  6. Sobel JD. Vulvovaginal candidiasis: a comparison of HIV-positive and-negative women. International journal of STD & AIDS. 2002;13(6):358-62.
  7. Makanjuola O, Bongomin F, Fayemiwo SA. An update on the roles of non-albicans Candida species in vulvovaginitis. Journal of Fungi. 2018; 4(4):121.
  8. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Frontiers in microbiology. 2017;7:2173.
  9. Arastehfar A, Daneshnia F, Hafez A, Khodavaisy S, Najafzadeh M-J, Charsizadeh A, et al. Antifungal susceptibility, genotyping, resistance mechanism, and clinical profile of Candida tropicalis blood isolates. Medical Mycology. 2020;58(6):766-73.
  10. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. Journal of clinical microbiology. 2005; 43(5): 2155-62.
  11. Vale-Silva LA, Sanglard D. Tipping the balance both ways: drug resistance and virulence in Candida glabrata. FEMS yeast research. 2015; 15(4):fov025.
  12. Ratner JC, Wilson J, Roberts K, Armitage C, Barton RC. Increasing rate of non-Candida albicans yeasts and fluconazole resistance in yeast isolates from women with recurrent vulvovaginal candidiasis in Leeds, United Kingdom. Sexually Transmitted Infections. 2025; 101(1):21-6.
  13. Won EJ, Choi MJ, Kim M-N, Yong D, Lee WG, Uh Y, et al. Fluconazole-resistant Candida glabrata bloodstream isolates, South Korea, 2008–2018. Emerging infectious diseases. 2021; 27(3):779.
  14. Kwon YJ, Shin JH. Candida and candidemia in Korea. Annals of Clinical Microbiology. 2024; 27(4).
  15. Wierzbicka A, Mańkowska-Wierzbicka D, Cieślewicz S, Stelmach-Mardas M, Mardas M. Interventions preventing vaginitis, vaginal atrophy after brachytherapy or radiotherapy due to malignant tumors of the female reproductive organs—A systematic review. International Journal of Environmental Research and Public Health. 2021;18(8):3932.
  16. Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS microbiology reviews. 2012;36(2):288-305.
  17. Wang F-J, Zhang D, Liu Z-H, Wu W-X, Bai H-H, Dong H-Y. Species distribution and in vitro antifungal susceptibility of vulvovaginal Candida isolates in China. Chinese medical journal. 2016; 129(10):1161-5.
  18. Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. American journal of obstetrics and gynecology. 1998;178(2):203-11.
  19. Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. The Lancet infectious diseases. 2018; 18(11): e339-e47.
  20. Aguin TJ, Sobel JD. Vulvovaginal candidiasis in pregnancy. Current infectious disease reports. 2015; 17:1-6.
  21. Sobel JD. Recurrent vulvovaginal candidiasis. American journal of obstetrics and gynecology. 2016;214(1):15-21.
  22. Odds FC. Candida and candidosis: a review and bibliography1988.
  23. Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Critical reviews in microbiology. 2016; 42(6): 905-27.
  24. Rodríguez-Cerdeira C, Gregorio MC, Molares-Vila A, López-Barcenas A, Fabbrocini G, Bardhi B, et al. Biofilms and vulvovaginal candidiasis. Colloids and Surfaces B: Biointerfaces. 2019;174:110-25.
  25. Mohamadi J, Havasian MR, Panahi J, Pakzad I. Antifungal drug resistance pattern of Candida. spp isolated from vaginitis in Ilam-Iran during 2013-2014. Bioinformation. 2015;11(4):203.
  26. Hedayati MT, Taheri Z, Galinimoghadam T, Aghili SR, Cherati JY, Mosayebi E. Isolation of different species of Candida in patients with vulvovaginal candidiasis from Sari, Iran. Jundishapur journal of microbiology. 2015; 8(4): e15992.
  27. Kent HL. Epidemiology of vaginitis. American journal of obstetrics and gynecology. 1991;165(4):1168-76.
  28. Ghajari A, Lotfali E, Ahmadi NA, Fassihi PN, Shahmohammadi N, Ansari S, et al. Isolation of different species of Candida in patients with vulvovaginal candidiasis from Damavand, Iran. Archives of Clinical Infectious Diseases. 2018; 13(6).
  29. Falahati M, Akhlaghi L, Abianeh M, Assadi M, Nami S, Fateh R. Prevalence of Candida albicans and Trichomonas vaginalis Infections in women. Life Sci J. 2013;10(5):479-83.
  30. Rad MM, Zafarghandi S, Abbasabadi B, Tavallaee M. The epidemiology of Candida species associated with vulvovaginal candidiasis in an Iranian patient population. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2011;155(2):199-203.
  31. Kiasat N, Rezaei-Matehkolaei A, Mahmoudabadi AZ, Mohamadpour KH, Molavi S, Khoshayand N. Prevalence of vulvovaginal candidiasis in Ahvaz, southwest Iran: a semi-large scale study. Jundishapur Journal of Microbiology. 2019;12(3):1-6.
  32. Khorsand I, Ghanbari Nehzag MA, Zarrinfar H, Fata A, Naseri A, Badiee P, et al. Frequency of variety of Candida species in women with Candida vaginitis referred to medical centers affiliated with Mashhad University of Medical Sciences during 2014-2015. Iranian Journal of Obstetrics, Gynecology and Infertility. 2015; 18(168):15-22.
  33. Jannati B, Pourdad A, Izadjoo A, Zarrinfar H, Najafzadeh MJ, Fata A. The Prevalence of Non-albicans Candida and Candida Mixed-species in Vulvovaginal Candidiasis in Northeast Iran. Clinical and Experimental Obstetrics & Gynecology. 2024;51(3):77.
  34. Nazeri M, Mesdaghinia E, Moravej SAR, Atabakhshiyan R, Soleymani F. Prevalence of vulvovaginal candidiasis and frequency of candida species in women. Journal of Mazandaran University of Medical Sciences. 2012; 21(86):254-62.
  35. Shokoohi G, Rasekh-Jahromi A, Solhjoo K, Hasannezhad A, Nouripour-Sisakht S, Ahmadi B, et al. Molecular characterization and antifungal susceptibility of Candida species isolated from vulvovaginitis in Jahrom City, south of Iran. Jundishapur J Microbiol. 2020;13(10):e106825.
  36. Mahmoudabadi AZ, Najafyan M, Alidadi M. Clinical study of Candida vaginitis in Ahvaz, Iran and susceptibility of agents to topical antifungal. Pak J Med Sci. 2010;26(3):607-10.
  37. Minooeianhaghighi MH, Sehatpour M, Zarrinfar H, Sen T. Recurrent vulvovaginal candidiasis: the causative agents, clinical signs and susceptibility to fluconazole in Gonabad city, northeast Iran. Current Women's Health Reviews. 2020;16(1):46-51.
  38. Khorsand I, Ghanbari Nehzag MA, Zarrinfar H, Fata A, Naseri A, Badiee P, et al. Frequency of variety of Candida species in women with Candida vaginitis referred to clinical centers of Mashhad, Iran. The Iranian Journal of Obstetrics, Gynecology and Infertility. 2015;18(168):15-22.
  39. Harville EW, Hatch MC, Zhang J. Perceived life stress and bacterial vaginosis. Journal of Women's Health. 2005;14(7):627-33.
  40. Paladine HL, Desai UA. Vaginitis: diagnosis and treatment. American family physician. 2018; 97(5):321-9.
  41. Hedayati MT, Taheri Z, Galinimoghadam T, Aghili SR, Cherati JY, Mosayebi E. Isolation of different species of Candida in patients with vulvovaginal candidiasis from Sari, Iran. Jundishapur journal of microbiology. 2015;8(4).
  42. ESMAEILZADEH S, MAHDAVI OS, Rahmani Z. Frequency and etiology of vulvovaginal candidiasis in women referred to a gynecological center in Babol, Iran. 2009.
  43. Hashemi SE, Shokohi T, Abastabar M, Aslani N, Ghadamzadeh M, Haghani I. Species distribution and susceptibility profiles of Candida species isolated from vulvovaginal candidiasis, emergence of C. lusitaniae. Current medical mycology. 2019;5(4):26.
  44. Bidaki MZ, Allahyari E, Ghanbarzadeh N, Nikoomanesh F. Using Artificial Neural Network to Predict Predisposing to Vulvovaginal Candidiasis among Vaginitis Cases. Mod Care J. 2024; 21:e135173.
  45. Mohammadi F, Hemmat N, Bajalan Z, Javadi A. Analysis of Biofilm‐Related Genes and Antifungal Susceptibility Pattern of Vaginal Candida albicans and Non‐Candida albicans Species. BioMed Research International. 2021; 2021(1):5598907.
  46. Salehei Z, Seifi Z, ZAREI MA. Sensitivity of vaginal isolates of Candida to eight antifungal drugs isolated from Ahvaz, Iran. 2012.
  47. Fouladi B, Rezaei Keikhaie K, Rajabpoor Nikoo N, Amini Poya S, Saravani S, Farzi J. Phenotypic evaluation of strains of Candida albicans and non-albicans Candida species in patients with vulvovaginal candidiasis visiting Amir-Al-Momenin hospital in Zabol, Iran in 2019. Journal of Obstetrics, Gynecology and Cancer Research. 2020;5(1):11-8.
  48. Sudbery PE. Growth of Candida albicans hyphae. Nature Reviews Microbiology. 2011; 9(10):737-48.
  49. Kaufman RH, Faro S, Brown D. Benign diseases of the vulva and vagina. (No Title). 1989.
  50. Pfaller M, Diekema D, Gibbs D, Newell V, Ellis D, Tullio V, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. Journal of clinical microbiology. 2010; 48(4):1366-77.
  51. Mohanty S, Xess I, Hasan F, Kapil A, Mittal S, Tolosa JE. Prevalence & susceptibility to fluconazole of Candida species causing vulvovaginitis. Indian Journal of Medical Research. 2007;126(3):216-9.
  52. Shirani K, Allameh Z, Moshtzan A. Identification of etiologic agents of recurrent vulvovaginal candidiasis in patients from Isfahan, Iran. Immunopathologia Persa. 2020; 7(2): e18-e.
  53. Deorukhkar SC, Saini S, Mathew S. Non‐albicans Candida infection: an emerging threat. Interdisciplinary perspectives on infectious diseases. 2014;2014(1):615958.
  54. Kołaczkowska A, Kołaczkowski M. Drug resistance mechanisms and their regulation in non-albicans Candida species. Journal of Antimicrobial Chemotherapy. 2016;71(6):1438-50.
  55. Shigemura K, Osawa K, Jikimoto T, Yoshida H, Hayama B, Ohji G, et al. Comparison of the clinical risk factors between Candida albicans and Candida non-albicans species for bloodstream infection. The Journal of antibiotics. 2014;67(4):311-4.
  56. Das KH, Mangayarkarasi V, Sen M. Antifungal resistant in non-albicans candida species are emerging as a threat to antenatal women with vulvovaginal candidiasis. Biomedical and Pharmacology Journal. 2019; 12(2):1369-78.
  57. Taei M, Chadeganipour M, Mohammadi R. An alarming rise of non-albicans Candida species and uncommon yeasts in the clinical samples; a combination of various molecular techniques for identification of etiologic agents. BMC research notes. 2019;12:1-7.
  58. Adampour Z, Hasanzadeh M, Zarrinfar H, Nakhaei M, Babi MN. Vaginitis Due to Pichia fermentans in a Patient Affected by Endometrial Cancer: A Novel Case Report. Current Women's Health Reviews. 2022;18(4):124-7.
  59. Kennedy MA, Sobel JD. Vulvovaginal candidiasis caused by non-albicans Candida species: new insights. Current infectious disease reports. 2010;12:465-70.
  60. Nejat ZA, Farahyar S, Falahati M, Khozani MA, Hosseini AF, Faiazy A, et al. Molecular identification and antifungal susceptibility pattern of non-albicans Candida species isolated from vulvovaginal candidiasis. Iranian biomedical journal. 2018;22(1):33.
  61. Rezaei-Matehkolaei A, Shafiei S, Zarei-Mahmoudabadi A. Isolation, molecular identification, and antifungal susceptibility profiles of vaginal isolates of Candida species. Iranian journal of microbiology. 2016;8(6):410.
  62. Farahyar S, Mobaser ZG, Razmjou E, Roudbary M, Rahimi M, Fattahi A. Molecular investigation of etiologic agents causing vulvovaginal candidiasis. Jundishapur Journal of Microbiology. 2020;13(8):1-7.
  63. Bonyadpour B, Akbarzdeh M, Mohagheghzadeh AA. A descriptive study on the prevalence of Vulvovaginal infections and species-specific distribution of Vulvovaginal Candidiasis in married women of the South of Iran. Journal of Midwifery and Reproductive Health. 2016;4(4):741-7.
  64. Khaksar Baniasadi A, Ayatollahi Mosavi SA, Sharifi I, Bamorovat M, Salari S, Ahmadi A, et al. Vulvovaginal candidiasis in Iranian women: Molecular identification and antifungal susceptibility pattern. Journal of Obstetrics and Gynaecology Research. 2022;48(12):3292-303.
  65. Gharaghani M, Ahmadi B, Sisakht MT, Ilami O, Aramesh S, Mouhamadi F, et al. Identification of Candida species isolated from vulvovaginal candidiasis patients by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in Yasuj southwestern Iran. Jundishapur Journal of Microbiology. 2018;11(8):1-4.
  66. Aslani N, Kokabi R, Moradi F, Abbasi K, Vaseghi N, Afsarian MH. Characterization of Candida species isolated from vulvovaginal candidiasis by MALDI-TOF with in vitro antifungal susceptibility profiles. Current medical mycology. 2021;7(4):6.
  67. Razzaghi-Abyaneh M, Sadeghi G, Zeinali E, Alirezaee M, Shams-Ghahfarokhi M, Amani A, et al. Species distribution and antifungal susceptibility of Candida spp. isolated from superficial candidiasis in outpatients in Iran. Journal de mycologie médicale. 2014;24(2): e43-e50.
  68. Salehi M, Ghasemian A, Mostafavi SKS, Nojoomi F, Ashiani D, Vardanjani HR. The epidemiology of Candida species isolated from urinary tract infections. Archives of Clinical Infectious Diseases. 2016;11(4):5.
  69. Seifi Z, Mahmoudabadi AZ, Zarrin M. Extracellular enzymes and susceptibility to fluconazole in Candida strains isolated from patients with vaginitis and healthy individuals. Jundishapur journal of microbiology. 2015;8(3).
  70. Mahmoudi Rad M, Zafarghandi A, Abbasabadi B, Amiri Z, Shivayi M, Amel Zabihi M, et al. Identification and comparison of etiologic agents in vulvovaginal candidiasis and recurrent vulvovaginal candidiasis by a differential medium. Research in Medicine. 2010;33(3): 189-94.
  71. Molazade p, khanjani n. The Prevalence of Infection and Antifungal Drug Susceptibility of Candida Vaginitis in Women Visiting Clinics in Kerman in 2013. Scientific Journal of Rafsanjan University of Medical Sciences. 2016; 14(12): 1061-72.
  72. Sharifynia S, Falahati M, Akhlaghi L, Foroumadi A, Fateh R. Molecular identification and antifungal susceptibility profile of Candida species isolated from patients with vulvovaginitis in Tehran, Iran. Journal of Research in Medical Sciences. 2017;22(1):132.
  73. Mohammadi-ghalehbin b, javanpour heravi h, arzanlou m, sarvi m. Prevalence and Antibiotic Resistance Pattern of Candida spp. Isolated from Pregnant Women Referred to Health Centers in Ardabil, Iran. Journal of Ardabil University of Medical Sciences and Health Services. 2017; 16(4): 409-21.
  74. Barmar P, Zarrinfar H, Jarahi L, Fata A. Comparison of Candida species in patients with Candida vulvovaginitis in Torbat-e Jam and its relationship with diabetes. The Iranian Journal of Obstetrics, Gynecology and Infertility. 2021; 23(11):60-7.
  75. Alizadeh M, Kolecka A, Boekhout T, Zarrinfar H, Nahzag MAG, Badiee P, et al. Identification of Candida species isolated from vulvovaginitis using matrix assisted laser desorption ionization-time of flight mass spectrometry. Current medical mycology. 2017 ;3(4):21.
  76. Seifi Z, Mahmoudabadi AZ, Zarrin M. Extracellular enzymes and susceptibility to fluconazole in Candida strains isolated from patients with vaginitis and healthy individuals. Jundishapur journal of microbiology. 2015; 8(3):e20162.
  77. Shokoohi G, Javidnia J, Mirhendi H, Rasekh‐Jahromi A, Rezaei‐Matehkolaei A, Ansari S, et al. Molecular identification and antifungal susceptibility profiles of Candida dubliniensis and Candida africana isolated from vulvovaginal candidiasis: A single‐centre experience in Iran. Mycoses. 2021;64(7):771-9.
  78. Holland J, Young M, Lee O, Chen SC. Vulvovaginal carriage of yeasts other than Candida albicans. Sexually transmitted infections. 2003;79(3):249-50.
  79. Mucci MJ, Cuestas ML, Landanburu MF, Mujica MT. Prevalence of Candida albicans, Candida dubliniensis and Candida africana in pregnant women suffering from vulvovaginal candidiasis in Argentina. Revista iberoamericana de micologia. 2017;34(2):72-6.

 

Journal of Patient Safety & Quality Improvement
Volume 13, Issue 2
April 2025
Pages 127-138

Files

Share

How to cite

Statistics